PMC:7544934 / 29454-29610 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T77","span":{"begin":0,"end":3},"obj":"https://glytoucan.org/Structures/Glycans/G00057MO"},{"id":"T78","span":{"begin":0,"end":3},"obj":"https://glytoucan.org/Structures/Glycans/G31736BK"}],"text":"LDN stimulates the release of β-endorphins by acting on the opioid receptor (Gold et al., 1982; The Uses of Low-Dose Naltrexone in Clinical Practice, 2020)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"712","span":{"begin":117,"end":127},"obj":"Chemical"}],"attributes":[{"id":"A712","pred":"tao:has_database_id","subj":"712","obj":"MESH:D009271"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"LDN stimulates the release of β-endorphins by acting on the opioid receptor (Gold et al., 1982; The Uses of Low-Dose Naltrexone in Clinical Practice, 2020)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T204","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"LDN stimulates the release of β-endorphins by acting on the opioid receptor (Gold et al., 1982; The Uses of Low-Dose Naltrexone in Clinical Practice, 2020)."}

{"project":"2_test","denotations":[{"id":"32930058-6289026-56195714","span":{"begin":90,"end":94},"obj":"6289026"}],"text":"LDN stimulates the release of β-endorphins by acting on the opioid receptor (Gold et al., 1982; The Uses of Low-Dose Naltrexone in Clinical Practice, 2020)."}